Sun Pharmaceuticals Industries Ltd P/E Ratio

The P/E Ratio of Sun Pharmaceuticals Industries Ltd is 40 as of 26 Jul 9.00 AM .a1#The P/E Ratio of Sun Pharmaceuticals Industries Ltd changed from 43.1 on March 2019 to 40.6 on March 2024 . This represents a CAGR of -0.99% over 6 years. a1#The Latest Trading Price of Sun Pharmaceuticals Industries Ltd is ₹ 1665 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.2 in 5 years. This represents a CAGR of -0.79%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.0. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Sun Pharmaceuticals Industries Ltd changed from ₹ 114988 crore on March 2019 to ₹ 388812 crore on March 2024 . This represents a CAGR of 22.51% over 6 years. a1#The Revenue of Sun Pharmaceuticals Industries Ltd changed from ₹ 10763 crore to ₹ 12588 crore over 8 quarters. This represents a CAGR of 8.15% a1#The EBITDA of Sun Pharmaceuticals Industries Ltd changed from ₹ 2886 crore to ₹ 3539 crore over 8 quarters. This represents a CAGR of 10.73% a1#The Net Pr of Sun Pharmaceuticals Industries Ltd changed from ₹ 2095 crore to ₹ 2666 crore over 8 quarters. This represents a CAGR of 12.80% a1#The Dividend Payout of Sun Pharmaceuticals Industries Ltd changed from 80.8 % on March 2019 to 113.33 % on March 2024 . This represents a CAGR of 5.80% over 6 years. a1#

Sun Pharmaceutical Industries Limited including its subsidiaries and associates (Sun Pharma) is the fourth largest global specialty generic company that is ranked No. In the year 1998, the company established their first research center, SPARC and this created the base for strong product and process development that enabled growth in the subsequent years. Also, the company acquired equity stake in Gujarat Lyka Organics Ltd., a manufacturer of Cephalexin Active with a USFDA approval for the intermediate, 7ADCA. In the year 1998, the company acquired a basket of products, including several respiratory/asthma brands acquired from Natco Pharma. During the year, the company completed the construction at a formulation manufacturing site at Jammu. In June 14, 2011, Caraco Pharmaceutical Laboratories Ltd (Caroco) merged with a subsidiary of the company. The Company announces USFDA approval for generic Prevacid, generic DoxilAr and generic DepoAr-Testosterone Injection. The acquired brands will be marketed by a reliable and established local marketing partner under the Sun Pharma label. The purpose of the buyback is to return surplus funds to the equity shareholders and thereby, enhancing the overall returns to shareholders. On 18 July 2016, Sun Pharma and Sun Pharma Advanced Research Company Ltd. (SPARC) announced a licensing arrangement for SPARC's ELEPSIA XR (Levetiracetam Extended Release tablets). Sun Pharma will be eligible to receive development and regulatory milestone payments and, additionally, sales milestone payments and royalties on net sales. It was the first branded product launched by the company in the USA following its focus on Specialty Business. On 22 December 2016, Sun Pharma announced its plans to acquire a branded oncology product Odomzo from Novartis. The agreement was signed for an upfront payment of US$ 175 million and additional milestone payments. The USFDA had taken action against the Mohali facility in 2013 when it ordered the facility to be fully subject to Ranbaxy's Consent Decree of Permanent Injunction. Sun Pharma will provide drug molecules to NIV for testing against Zika, Chikungunya and Dengue in model systems. These RTA bags will provide greater safety, by preventing problems of over-dosing or under-dosing and eliminating contamination risk. In August 2019, Sun Pharma granted an exclusive license to a subsidiary of China Medical System Holdings Ltd. (CMS) to develop and commercialise seven generic products in Mainland China. In November 2019, Sun Pharma entered into a licensing agreement with AstraZeneca UK Ltd. (AstraZeneca) to introduce certain novel ready to use (RTU) infusion oncology products in China. It initiated Phase-2 clinical trials for a potential oral treatment for atopic dermatitis and moderate to severe plaque psoriasis.